PTGS2 and cancer: ‘Master modulators’ of tumors, i.e., transcriptional modulators, metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs, etc., are aiming at attenuation of cancer-associated hallmarks or at establishing novel biologic hallmarks linked to tumor control.